Our Pipeline
At Alivexis, based on the experience and knowledge cultivated over time, we are currently focusing on cancer, immune-inflammatory diseases, and rare diseases.
Our lead molecules include modulators of innate immunity including neutrophil, mast cell, and eosinophil related inflammation pathways, exquisitely selective inhibitors for oncogenic driver kinases including novel allosteric inhibitors, and inhibitors targeting the DNA damage response pathway with potential MOA involving synthetic lethality.
The most advanced project in the pipeline is as follows
MOD-A: Non-Covalent CatC Inhibitor
MOD-A represents a pivotal project within Alivexis’ pipeline, focusing on the development of a non-covalent inhibitor targeting Cathepsin C, a crucial enzyme implicated in the regulation of multiple proteases involved in tissue destruction through the excessive activation of neutrophils. The identified clinical candidate compound, MDI-0151, has demonstrated efficacy in disease models of neutrophil-driven inflammation, such as the ANCA-associated vasculitis model. Given its mechanism of action, MDI-0151 holds the potential for efficacy beyond vasculitis, including in respiratory diseases like bronchiectasis and chronic obstructive pulmonary disease (COPD), skin conditions such as hidradenitis suppurativa and palmoplantar pustulosis, as well as a broad range of chronic diseases including inflammatory bowel disease and systemic lupus erythematosus.
MOD-B: Highly Specific KIT Inhibitor
MOD-B project involves a compound that inhibits KIT, a membrane receptor that plays a crucial role in various functions, including the activation and survival of mast cells, with unprecedented high selectivity. We have already identified the clinical candidate compound MDI-0238 and have confirmed its efficacy in models of acute and chronic mast cell-related diseases, such as anaphylaxis and food allergies. Given its mechanism of action, it is believed to be effective for a wide range of both acute and chronic diseases, including chronic urticaria, asthma, and eosinophilic esophagitis.
MOD-C: PARG Inhibitor
MOD-C is a pivotal project within the Alivexis pipeline, focused on developing a novel anticancer agent through targeting PARG, a key enzyme involved in DNA damage repair. The project has successfully identified MDI-0355 as its clinical candidate compound. MDI-0355 has demonstrated efficacy as a monotherapy in animal models using cancer cells with specific genetic profiles. Furthermore, when used in combination with existing chemotherapeutic agents, emerging targeted therapies, and even radiation therapy, MDI-0355 has confirmed efficacy in extending its therapeutic effects across a broad range of cancer types.
MOD-D: WDR5 Inhibitor
This is a project for an anticancer drug targeting WDR5, a scaffold protein in the transcription complex involved in the signal of the transcription factor myc, which plays an important role in a wide variety of cancer types. We have already observed tumor shrinkage effects in animal models using cancer cells with a specific genetic profile with our own lead compound, and we are in the final stage toward the discovery of a clinical candidate compound.
MOD-E: DGKα Selective Inhibitor
This project involves a cancer immunotherapy activator targeting DGKα, which serves as a brake on the activation of T cells, one of the immune cells that govern cancer immunity. We have already confirmed the efficacy of our own lead compound as a single agent, as well as its synergistic effect in combination with anti-PD-1 antibodies in animal models, and we are in the final stage of discovering a clinical candidate compound.
ALVX-A: PKMYT1 Selective Inhibitor
This project involves an anticancer agent targeting PKMYT1, one of the molecules that governs the cell cycle in cancer and acts protectively in cancer cells. We have already observed tumor shrinkage effects as a single agent in animal models using cancer cells with a specific genetic profile with our own lead compound, and we are in the final stage toward the discovery of a clinical candidate compound.
Other: There are early-stage projects for cancer, immune-inflammatory diseases, and rare diseases, including multiple programs focused on the discovery of allosteric inhibitors as part of a collaboration program with PeptiDream.
Partnering Information
All ownership rights of our pipeline programs are held by Alivexis, and we are actively seeking potential partners and look forward to inquiries about any collaboration opportunities.
Furthermore, Alivexis actively participates in drug discovery partnerships, capitalizing on our proven, robust platform technology that has successfully yielded a multitude of unique clinical candidate compounds, among other significant advantages. We invite you to explore collaboration opportunities with Alivexis, leveraging our broad expertise from target identification through to the discovery and profiling of clinical candidate compounds.
Please contact us here for further inquiries.